Evaluation of Major Cardiovascular Events in Patients With or at High Risk for Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo

    Not Recruiting
  • End date
    Mar 7, 2022
  • participants needed
  • sponsor
    Esperion Therapeutics
Updated on 24 January 2021
Stephanie Kelly
Primary Contact
(4.8 mi away) Contact
+471 other location
peripheral vascular disease
hmg-coa reductase inhibitor


The purpose of this study is to determine if treatment with bempedoic acid (ETC-1002) versus placebo decreases the risk of cardiovascular events in patients who are statin intolerant.

Condition Cardiovascular Disease, Statin Adverse Reaction
Treatment Bempedoic acid 180 mg tablet, Matching placebo tablet
Clinical Study IdentifierNCT02993406
SponsorEsperion Therapeutics
Last Modified on24 January 2021

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note